5269 Results for: "Enzo Life Sciences"

Supplier: Enzo Life Sciences

FP receptor agonist.

Supplier: Enzo Life Sciences

Host: Mouse, Isotype: IgG1

Supplier: Enzo Life Sciences

Host: Rabbit

Supplier: Enzo Life Sciences

Immunomodulator.

Supplier: Enzo Life Sciences

Cytochrome P450 inducer.

Supplier: Enzo Life Sciences

Inhibits the translocation of Akt.

Supplier: Enzo Life Sciences

URB-597 is a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), which is involved in the hydrolysis of endogenous cannabinoids such as anandamide. Inhibition of FAAH may serve to enhance the analgesic effects of endogenous cannabinoids. URB-597 has been shown to inhibit FAAH in rat cortical neuron membranes and in intact neurons with IC50 values of 4.6nM and 0.5nM, respectively. The compound has also been shown to have anxiolytic effects in rats (ID50=0.15mg/kg). Because URB-597 acts on FAAH and does not interfere with the binding of anandamide to the CB1 and CB2 receptors, it is a novel tool for drug development.

Supplier: Enzo Life Sciences

Tyrosine kinase inhibitor. It has been shown to block TNFα induced cytotoxicity and to block glucocorticoid-induced COX-2 activity in human amnion cells (IC50=21μM). It is also reported to inhibit guanylyl cyclase.

Supplier: Enzo Life Sciences

Cathepsin inhibitor

Supplier: Enzo Life Sciences

Plant H+-ATPase activator.

Supplier: Enzo Life Sciences

ADP-ribosylation factor inhibitor

Supplier: Enzo Life Sciences

Host: Mouse, Isotype: IgG1

Supplier: Enzo Life Sciences

Retinoic acid receptor ligand

Supplier: Enzo Life Sciences

HNMPA is a membrane impermeable inhibitor of insulin receptor tyrosine kinase (IC50 = 100µM); in rat adipocytes (IC50 = 10µM). Inhibits serine and tyrosine autophosphorylation by the human insulin receptor.

Supplier: Enzo Life Sciences

NF-kappaB inhibitor

Supplier: Enzo Life Sciences

Potent antitumor antibiotic. Inhibitor of pp60^src tyrosine kinase and of c-myc gene expression in murine lymphoblastoma cells. Inhibits the transforming activity of abl, erbB, fps, src, and yes.

Supplier: Enzo Life Sciences

DRB is a potent and specific inhibitor of casein kinase II (CKII, IC50~6 µM). It has been used to inhibit RNA polymerase II mediated-transcription which may be dependent on CKII and its interaction with ATF-1.

Supplier: Enzo Life Sciences

Active enantiomer of ketoprofen. Inhibits cyclooxygenase.

Supplier: Enzo Life Sciences

Cell-permeable PKC inhibitor. Selective for PKC (IC50=10nM) over CaM kinase II (IC50=17µM) and PKA (IC50=0.9µM). Induces apoptosis in various cell lines.

Supplier: Enzo Life Sciences

Damnacanthal is a potent and selective inhibitor of p56lck tyrosine kinase. It inhibits p56lck autophosphorylation (IC50=17 nM) as well as phosphorylation of exogenous substrates (IC50=620 nM) in cell-free assays. Damnacanthal shows a 10-fold selectivity for p56lck over PKA and PKC and 40-fold selectivity over four receptor tyrosine kinases as well as 7–20-fold selectivity over the homologous enzymes p60src and p59fyn.

Supplier: Enzo Life Sciences

Produced in E. coli. The enzyme is cleaved and activated from the proenzyme.

Supplier: Enzo Life Sciences

Produced in E. coli. Human caspase-7 (aa 24-303). Genbank Accession No. U40281.

Supplier: Enzo Life Sciences

Inhibitory iODN oligodeoxynucleotide with phosphorothioate backbone. Sequence of an inhibitory ODN for in vivo use in rodents (50-150µg per injection): prototype class I that potently inhibits TLR9 and TLR7 signaling.

Supplier: Enzo Life Sciences

Spin trapping reagent

Supplier: Enzo Life Sciences

SOD mimetic. Peroxynitrite scavenger.

Supplier: Enzo Life Sciences

Isolated from Griffonia (Bandeiraea) simplicifolia seeds.

Supplier: Enzo Life Sciences

TLR9 activator.

Supplier: Enzo Life Sciences

Host: Rat, Isotype: IgG2a

Supplier: Enzo Life Sciences

P62, also known as Sequestosome I, is a 62kDa, 440 amino acid protein, initially identified as a ligand of the SH2 domain of p56lck, now known to be expressed in many tissues. In addition to TRAF6, PEST and zinc finger motifs, p62 has a C-terminal ubiquitin binding association (UBA) domain with an affinity for multi-ubiquitin chains, and it is considered to serve as a scaffold protein, capable of binding to multiple signalling molecules and uniting receptor-mediated signalling events with ubiquitinylation. Elevated levels of p62 have been reported in breast tumours and in alcoholic liver disease where p62 has been shown to be involved in the formation of Mallory bodies. Several mutations in the p62 UBA domain have been identified and the etiology of Paget’s disease of bone has been linked to one such mutation. Kuusisto and colleagues have demonstrated that p62 is also present in elevated levels in the hallmark inclusions found in various neurodegenerative conditions, including tauopathies (Alzheimer’s disease, Picks disease, and frontotemporal dementia) and synucleinopathies (Parkinson’s disease, dementia with Lewy body disease and multiple system atrophy). In recent years ubiquitin immunostaining has been used to provide adjunct information for neuropathological diagnosis, but it is becoming evident that p62 may be an even more reliable marker of neurodegenerative disease inclusion detection than tau, alpha-synuclein or ubiquitin immunostaining.

Supplier: Enzo Life Sciences

Non-selective Ca²⁺ channel blocker. Stimulates the binding of 1,4-dihydropyridine-based drugs to Ca²⁺ channels. Inhibits Na⁺/Ca²⁺ exchange.